Sort by
Refine Your Search
-
Listed
-
Employer
- Eindhoven University of Technology (TU/e)
- Erasmus University Rotterdam
- Leiden University
- Utrecht University
- Delft University of Technology (TU Delft)
- Leiden University; yesterday published
- Radboud University
- University of Amsterdam (UvA)
- DIFFER
- Eindhoven University of Technology (TU/e); today published
- University of Groningen
- University of Twente (UT)
- DIFFER; Eindhoven
- Delft University of Technology (TU Delft); today published
- Delft University of Technology (TU Delft); yesterday published
- Eindhoven University of Technology (TU/e); yesterday published
- University of Amsterdam (UvA); Amsterdam
- University of Twente
- AMOLF
- ARCNL
- Delft University of Technology (TU Delft); Published yesterday
- Eindhoven University of Technology (TU/e); 4 Oct ’25 published
- Erasmus University Rotterdam (EUR)
- Erasmus University Rotterdam (EUR); yesterday published
- KNAW
- Leiden University; today published
- Maastricht University (UM)
- Maastricht University (UM); 26 Sep ’25 published
- Max Planck Institute for the Study of Crime, Security and Law; Published yesterday
- University Medical Center Utrecht (UMC Utrecht)
- University Medical Center Utrecht (UMC Utrecht); today published
- University Medical Centre Groningen (UMCG); today published
- University of Amsterdam (UvA); Published 21 Nov ’25
- University of Amsterdam (UvA); Published yesterday
- University of Amsterdam (UvA); yesterday published
- University of Groningen; 26 Sep ’25 published
- University of Groningen; Published 28 Nov ’25
- University of Groningen; Published yesterday
- University of Twente (UT); Enschede
- University of Twente (UT); Published today
- Utrecht University; Utrecht
- Utrecht University; Published today
- Utrecht University; Published yesterday
- Utrecht University; today published
- Vrije Universiteit Amsterdam (VU)
- Wageningen University & Research
- 36 more »
- « less
-
Field
-
, targeted drug delivery, and personalized therapy at the molecular level. By exploiting nanoscale materials and systems, it allows drugs to reach specific cells or tissues while minimizing side effects and
-
transformative frontier in modern healthcare, enabling precise diagnosis, targeted drug delivery, and personalized therapy at the molecular level. By exploiting nanoscale materials and systems, it allows drugs
-
an uncertain future, and hoping that targeted policy and planning help cities to move into new and better states. Therefore, this project focuses on three questions: (1) Under what combination of conditions do
-
mainly about substances that are problematic in light of their poor degradability, high toxicity or tendency to accumulate at non-targeted sites. The Environmental Risk Assessment framework developed
-
as a cornerstone of the net-zero transition is driven by ambitious goals and targets set by the European Commission, among others, under the European Green Deal. Achieving these targets is expected
-
as a cornerstone of the net-zero transition is driven by ambitious goals and targets set by the European Commission, among others, under the European Green Deal. Achieving these targets is expected
-
PhD position understanding and designing nanomedicines-membranes interaction: physics based approach
the nanomedicines with high specificity to the desired target site in the body. In this PhD project, the candidate will experimentally study how to achieve high specificity by developing a quantitative understanding
-
assessment processes (i.e., Constructive Alignment) when the set of learning outcomes is non-predefined. We aim to contribute a set of validated design principles and solutions for various target groups and
-
imaging practices, RHYTHM targets key challenges in justification, optimisation, availability, and accessibility of imaging services. The RHYTHM project addresses key challenges in justification
-
immunoextraction of full proteins and SISCAPA-based peptide extraction, and develop targeted bottom-up proteomics methods using mass spectrometry. Additionally, you will engineer full proteins and signature peptides